Pharma BD Deal Intelligence

Sanofi SA / Hanmi Pharmaceutical Co., Ltd. (Quantum Project)

2015 · Licensing/Option · $4.2B · Terminated

Sanofi acquired exclusive worldwide rights to Hanmi's three-asset Quantum Project diabetes portfolio (efpeglenatide, weekly insulin, weekly GLP-1/insulin combo) for euro 400M (~$435M) upfront plus up to euro 3.5B (~$3.77B) in milestones plus double-digit royalties. Sanofi returned partial rights December 2016 (insulin and combo product); efpeglenatide rights returned to Hanmi in May 2020.

Key facts

• Announced Nov 05, 2015
• Closed Nov 05, 2015
• Deal value $4.2B
• Deal type Licensing/Option
• Therapeutic area Type 2 diabetes mellitus
• Indications Type 2 diabetes mellitus
• Key assets Efpeglenatide; weekly insulin; weekly GLP-1/insulin combination ('Quantum Project')
• Mechanism Long-acting GLP-1 receptor agonist and basal insulin (LAPSCOVERY platform)

← Browse all deals  ·  How we score deals